Volume | 83,256 |
|
|||||
News | - | ||||||
Day High | 109.6225 | Low High |
|||||
Day Low | 107.28 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Glaukos Corporation | GKOS | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
108.09 | 107.28 | 109.6225 | 107.44 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,416 | 83,256 | US$ 108.84 | US$ 9,061,351 | - | 54.3801 - 113.97 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
11:50:04 | 1 | US$ 109.3436 | USD |
Glaukos Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.41B | 49.47M | - | 314.71M | -134.66M | -2.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Glaukos News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GKOS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 110.84 | 110.84 | 106.13 | 108.63 | 345,222 | -1.55 | -1.40% |
1 Month | 100.28 | 113.97 | 95.39 | 105.75 | 448,837 | 9.01 | 8.98% |
3 Months | 88.59 | 113.97 | 83.90 | 96.63 | 483,708 | 20.70 | 23.37% |
6 Months | 63.09 | 113.97 | 59.22 | 88.12 | 663,920 | 46.20 | 73.23% |
1 Year | 57.89 | 113.97 | 54.3801 | 80.20 | 584,719 | 51.40 | 88.79% |
3 Years | 75.36 | 113.97 | 33.33 | 62.22 | 521,467 | 33.93 | 45.02% |
5 Years | 64.80 | 113.97 | 23.31 | 59.85 | 534,208 | 44.49 | 68.66% |
Glaukos Description
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |